CPP
NBIX icon

Crow Point Partners’s Neurocrine Biosciences NBIX Stock Holding History

Crow Point Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,776
Closed -$218K – 149
2018
Q3 		$218K Buy
+1,776
New +$202K 0.04% 145
2018
Q2 		– Sell
-2,728
Closed -$226K – 198
2018
Q1 		$226K Buy
2,728
+810
+42% +$68.4K 0.04% 95
2017
Q4 		$145K Buy
+1,918
New +$131K 0.02% 147

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Crow Point Partners's NBIX Position: Q4 2018 in Review

Crow Point Partners sold out of Neurocrine Biosciences (NBIX) in Q4 2018, closing a stake of 1,776 shares — an estimated $218K sold.

Crow Point Partners first reported a position in NBIX in Q4 2017 and held it in 3 quarters. The position peaked at $226K in Q1 2018. 330 funds tracked by Wall St. Rank hold NBIX as of Q4 2018.

  • Crow Point Partners reported no remaining Neurocrine Biosciences position as of Q4 2018 after selling out during the quarter.
  • Crow Point Partners sold 1,776 Neurocrine Biosciences shares in Q4 2018, an estimated $218K.
  • Crow Point Partners first reported a position in Neurocrine Biosciences in Q4 2017 and held it in 3 quarters.
  • Crow Point Partners's Neurocrine Biosciences position peaked at $226K in Q1 2018.
  • 330 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2018.

Based on Crow Point Partners's 13F filing for Q4 2018, filed 14 Feb 2019.